Analysts Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Target Price at $6.55

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven analysts that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $6.55.

A number of brokerages recently weighed in on GDRX. Wells Fargo & Company decreased their price objective on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Truist Financial cut their target price on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research report on Thursday, April 10th. The Goldman Sachs Group cut their target price on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, UBS Group cut their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research report on Tuesday, May 13th.

Insider Activity

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.53% of the stock is currently owned by insiders.

Institutional Investors Weigh In On GoodRx

Hedge funds have recently modified their holdings of the business. National Bank of Canada FI grew its position in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after acquiring an additional 2,151 shares during the period. Citizens Financial Group Inc. RI bought a new stake in shares of GoodRx during the 1st quarter valued at $44,000. Jump Financial LLC bought a new stake in shares of GoodRx during the 1st quarter valued at $49,000. RPO LLC purchased a new position in shares of GoodRx during the 4th quarter valued at $52,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in shares of GoodRx during the 4th quarter valued at $56,000. Institutional investors own 63.77% of the company's stock.

GoodRx Stock Down 2.1%

Shares of GDRX stock traded down $0.11 during trading hours on Thursday, hitting $4.80. 558,764 shares of the company's stock traded hands, compared to its average volume of 1,428,316. The stock's fifty day simple moving average is $4.36 and its two-hundred day simple moving average is $4.53. GoodRx has a 12-month low of $3.68 and a 12-month high of $9.26. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of 59.94, a PEG ratio of 2.17 and a beta of 1.24. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. GoodRx had a net margin of 3.57% and a return on equity of 7.85%. The company had revenue of $202.97 million during the quarter, compared to analyst estimates of $202.25 million. During the same period in the previous year, the business earned $0.08 EPS. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. On average, analysts expect that GoodRx will post 0.13 EPS for the current year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.